P
Peter Davidson
Researcher at University of Southampton
Publications - 40
Citations - 1541
Peter Davidson is an academic researcher from University of Southampton. The author has contributed to research in topics: Clinical trial & Cost effectiveness. The author has an hindex of 16, co-authored 40 publications receiving 1380 citations. Previous affiliations of Peter Davidson include National Institute for Health Research.
Papers
More filters
Journal ArticleDOI
Adefovir dipivoxil and pegylated interferon alpha for the treatment of chronic hepatitis B: an updated systematic review and economic evaluation
TL;DR: Both ADV and PEG-alpha are beneficial for patients with CHB in terms of suppressing viral load, reducing liver damage-associated biochemical activity, inducing HBeAg seroconversion, and reducing liver fibrosis and necroinflammation.
Journal ArticleDOI
Informing efficient randomised controlled trials: exploration of challenges in developing progression criteria for internal pilot studies.
Kerry N L Avery,Paula R Williamson,Carrol Gamble,Elaine O'Connell Francischetto,Chris Metcalfe,Peter Davidson,Hywel C Williams,Jane M Blazeby,Natalie S Blencowe,Carol Bugge,Michael J. Campbell,Michelle Collinson,Cindy Cooper,Janet Darbyshire,Munya Dimairo,Caroline J Doré,Sandra Eldridge,Amanda Farrin,Nadine E. Foster,Simon Gilbody,Steve Goodacre,Lisa V. Hampson,Angelos G. Kolias,Sallie Lamb,Athene Lane,Lisa Maguire,John Norrie,Ruth M. Pickering,Gillian W Shorter,Shaun Treweek +29 more
TL;DR: Systematic and transparent reporting of the design, results and evaluation of internal pilot trials in the literature should be encouraged in order to facilitate understanding in the research community and to inform future trials.
Journal ArticleDOI
Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C : a systematic review and economic evaluation
TL;DR: It is shown that patients with histologically mild HCV can be successfully treated with both pegylated and non-pegylated interferon alfa, and early treatment and watchful waiting strategies are associated with acceptable cost-per-QALY estimates.
Journal ArticleDOI
Clinical effectiveness and cost-effectiveness of immediate angioplasty for acute myocardial infarction: systematic review and economic evaluation.
Debbie Hartwell,Jill L Colquitt,Emma Loveman,Andrew Clegg,H. Brodin,Norman Waugh,Pamela Royle,Peter Davidson,Luke Vale,L. MacKenzie +9 more
TL;DR: PCI is more cost-effective than thrombolysis, providing additional benefits in health status at some extra cost, and if both interventions were routinely available, the economic analysis favours PCI.
Journal ArticleDOI
Topical corticosteroids for atopic eczema: clinical and cost effectiveness of once-daily vs. more frequent use.
TL;DR: Topical corticosteroids remain the mainstay of treatment for atopic eczema, yet there is uncertainty over the frequency of their use in terms of clinical and cost effectiveness.